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Abstract: Genomic instability is a hallmark of human cancer and an enabling factor for the genetic
alterations that drive cancer development. The processes involved in genomic instability resemble
those of meiosis, where genetic material is interchanged between homologous chromosomes. In most
types of human cancer, epigenetic changes, including hypomethylation of gene promoters, lead to the
ectopic expression of a large number of proteins normally restricted to the germ cells of the testis. Due
to the similarities between meiosis and genomic instability, it has been proposed that activation of
meiotic programs may drive genomic instability in cancer cells. Some germ cell proteins with ectopic
expression in cancer cells indeed seem to promote genomic instability, while others reduce polyploidy
and maintain mitotic fidelity. Furthermore, oncogenic germ cell proteins may indirectly contribute to
genomic instability through induction of replication stress, similar to classic oncogenes. Thus, current
evidence suggests that testis germ cell proteins are implicated in cancer development by regulating
genomic instability during tumorigenesis, and these proteins therefore represent promising targets
for novel therapeutic strategies.
Keywords: genomic instability; cancer development; testis germ cell proteins; mitosis; polyploidy;
mitotic fidelity
1. Introduction
In normal cells, genomic stability is maintained by multiple highly controlled mechanisms that
secure fidelity of DNA replication during S phase, segregation of chromosomes during mitosis, and
precise repair of DNA damage throughout the cell cycle [1]. Genomic instability, on the other hand, is a
hallmark of almost all human cancers and is acknowledged as a main driving force of tumorigenesis [2].
Changes in the genome resulting from genomic instability include mutations, rearrangements of
chromosomes, gain or loss of partial or whole chromosomes, etc. In most cases, a significant change
to the genome results in a non-viable cell, but in rare events it might confer a selective advantage on
a specific cell leading to cancer initiation or progression [2]. The development of high-throughput
techniques for DNA sequencing has enabled large-scale analysis of cancer genomes to identify common
and rare genomic alterations that may support tumorigenesis. As expected, such genomic changes
often involve genes encoding tumor suppressors or proto-oncogenes. For instance, the TP53 gene is
deleted or mutated in more than 50% of human cancers, resulting in abolished function of the encoded
p53 tumor suppressor [3]. Similarly, proto-oncogenes can be activated by mutations (e.g., KRAS [4],
BRAF [4], EGFR [5]), focal amplification (e.g., HER2 [6], EGFR [7]) or genomic rearrangements creating
fusion oncogenes (e.g., BCR-ABL [8], SYT-SSX [9]). Recent evidence further demonstrates that genomic
alterations in noncoding regions can also support tumorigenesis. For instance, mutations or deletions
in neighborhood insulators (i.e., genetic boundary elements that block interaction between enhancers
and promoters) are found in many types of cancer and are sufficient for activation of oncogenes [10].
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Thus, it is well documented that accumulation of genomic alterations in tumors is not only a hallmark,
but also a driving force of tumorigenesis in many cancers.
While the consequences of genomic instability in cancers are relatively well-characterized,
the causes of genomic instability remain to be clearly defined. It is expected that disruption of processes
that function to maintain genome integrity, including the DNA repair system, the chromosome
segregation system and multiple cell cycle progression checkpoints, is important in tumorigenesis.
Indeed, many types of hereditary cancers are driven by germline mutations in, for instance, DNA
repair genes [11–13]. However, mutations, for example, in cell cycle checkpoint and DNA repair genes
are only present in 31% of sporadic cancers [14–17]. In the remaining cancers, expression of oncogenes
may account for some of the observed genomic instability as a consequence of oncogene-induced
replication stress [18].
Recent results suggest that another driver of genomic instability in tumors may be ectopic
expression of germ cell genes. Over the last two decades, hundreds of genes that are normally only
expressed in the germ cells of the testis have been identified as ectopically expressed in multiple types
of human cancer [19,20]. One of the possible reasons for this widespread activation of testis genes
in cancer seems to be epigenetic dysregulation resulting in hypomethylation of CpG islands in the
regulatory elements of these genes [20–26]. Many of the encoded proteins are immunogenic when
expressed in patient tumors and have been termed cancer/testis antigens [20]. Due to their restricted
expression pattern and immunogenic properties, cancer/testis antigens have attracted a lot of attention
as potential therapeutic targets. These testes germ cell proteins participate in specialized processes of
spermatogenesis, which include sustaining a pool of highly proliferative spermatogonial stem cells and
several stages of cellular differentiation into mature sperm. A central element in spermatogenesis is
meiosis, where chromosomes duplicate and recombine to exchange genetic material. Recent evidence
suggests that ectopic expression of testis germ cell proteins in somatic cells, especially meiosis proteins,
can interfere with genomic stability and promote tumorigenesis.
2. The Role of Meiotic Proteins in Tumorigenesis
Meiosis is a unique feature of germ cells and partly functions to create genetic diversity. Meiosis
and mitosis share many features, but while mitosis serves to produce two genetically identical
diploid cells, meiosis produces four genetically different haploid gametes. Once germ cells are
committed to spermatogenic differentiation, they lose their proliferative capacity and enter the meiosis
cycle [27], a process highly controlled by various proteins and complexes. For instance, alignment of
the homologous chromosomes is mediated by the synaptonemal complex, while the sister chromatids
remain attached by the meiotic chromosome cohesin complex and numerous proteins act in concert
to initiate and ensure homologous recombination (reviewed in [28]). Many meiotic proteins are
expressed in cancers and may perturb mechanisms maintaining genomic stability (Table 1). For
instance, activation of germ cell programs in cancer cells has the capacity to promote chromosomal
rearrangements and loss or gain of whole chromosomes (Figure 1).
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Table 1. List of meiotic proteins that potentially regulate genomic instability in cancer.
Protein Function in Meiosis Species of Functional Studies Expression in Cancer
PRDM9 Meiotic recombination hotspotactivator [29–31] Mice and human protein
Embryonal carcinoma, astrocytoma, colon, prostate, breast, ovary, melanoma and leukemia
cancer cell lines [32]
SPO11 Meiosis-specific nuclease [29,33,34] Mice and yeast Melanoma and lung cancer cell lines, and melanoma and cervical cancer tissue [35,36]
TEX15 Mediates loading of DSB repair proteinsonto DNA (at DSB sites) [37] Mice
Bladder carcinomas, cutaneous melanoma, esophageal carcinomas, head and neck carcinomas,
lung carcinoma, neuroblastomas, prostate tumors, renal tumors and sarcomas [38]
DMC1 Recombinase/DNA repair protein [39] Human protein Cervical cancer tissue [40]
MEIOB 31 to 51 exonuclease [41–43] Mice and human cell lines Liver, leukemia and lung cancer cell lines [41]
HORMAD1
Mediates homologous recombination,
synaptonemal complex formation and
recruitment of ATR kinase activity to
unsynapsed chromatin [44,45]
Mice
Gastric [46], breast (including triple-negative breast cancer), non-small cell lung cancer
(NSCLC), esophageal, endometrical, bladder and colon cancer tissue [47,48], and breast,
ovarian, melanoma, cervical, NSCLC and small lung cancer cell lines (CT Gene Database) [48]
HORMAD2 Proposed function: Similar toHORMAD1 [49,50] Mice Lung cancer tissue [51]
SCP-3/SYCP3 Synaptonemal complex protein [52] Mice NSCLC [53] and cervical cancer tissue [54]
SYCE1 Synaptonemal complex protein [55] Mice Breast cancer, melanoma and leukemia cancer cell lines (CT Gene Database)
SCP-1/SYCP1 Synaptonemal complex protein [56] Human cell line
Breast, melanoma, brain (glioma, glioblastoma, schwanoma, medulloblastoma, meningioma,
astrocytoma, oligoastrocytoma and pilocytic astrocytoma), gastric, lung (including NSCLC),
renal cell, stomach [57–61] and pancreatic cancer tissue [62], and ovarian (CT Gene Database),
ATLL [63] and pancreatic [62] cancer cell lines
REC8 Component of meiosis-specific cohesincomplex [64–67] Mice Melanoma cell lines [35,68]
RAD21L Component of meiosis-specific cohesincomplex [64–67] Mice Colon, breast, ovarian, embryonal carcinoma, cervix and leukemia cancer cell lines [32]
SMC1β Component of meiosis-specific cohesincomplex [64–67] Mice Breast, leukemia and embryonal carcinoma cancer cell lines [32]
STAG3 Component of meiosis-specific cohesincomplex [64–67] Mice Various cancers (reported in Oncomine, September 2012)
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Table 1. Cont.
Protein Function in Meiosis Species of Functional Studies Expression in Cancer
AURKC Component of the of the meioticchromosomal passenger complex [69,70] Mice and human cell lines
Breast, cervical, liver, prostate, thyroid carcinoma cancer cells lines [71–73], and colorectal and
thyroid cancer tissue [71,74]
MOS Regulates oocyte maturation [75] Xenopus Ovarian cancer tissue [76] and neuroblastoma and cervical carcinoma-derived cell lines [77]
ACRBP Role in spermatogenesis and spermcapacitation [78,79] Porcine
Ovarian cancer cell line and cancer tissue [80], bladder, breast, lung, liver and colon cancer
tissue [81], and sarcoma, prostate, multiple myeloma, chronic myeloid leukemia, lung and
ovarian cancer cell lines (CT Gene Database)
FMR1NB
Role in regulating microtubule nucleation
and/or anchoring events in the mitotic
spindle (suggested role from CT Gene
Database, based on [82])
Human cell lines
Melanoma, sarcoma, lung, breast, bladder, esophageal and ovarian cancer tissue [83], and
sarcoma, multiple myeloma, chronic myeloid leukemia, choriocarcinoma, lung and breast
cancer cell lines (CT Gene Database)
NXF2
Nuclear RNA export factor, important for
regulation of meiosis and maintenance of
spermatogonial stem cells [84]
Mice
Melanoma, sarcoma, prostate, multiple myeloma, chronic myeloid leukemia, choriocarcinoma,
lung, ovarian and colon cancer cell lines (CT Gene Database), and bladder, colorectal
carcinoma, lung, melanoma, esophageal, head and neck, neuroblastoma, prostate, sarcoma and
thyroid cancer tissue [38]
MAGEA5 Breast [85], lung, head and neck [86], lung adenocarcinoma and squamous cell cancertissue [87], and melanoma and thyroid carcinoma cell lines [88]
FSIP1 Component of the fibrous sheath structure,unique for spermatogenic cells [89] Mice and yeast Breast cancer tissue [90,91]
TACC3 Mitosis: Plays a role in spindle stability andkinetochore-microtubule interactions [92] Human cell lines Breast, lung, colon and liver cancer tissue [93]
STARD6 Involved in transport of lipids [94] Mice
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2.1. Proteins Involved in Meiotic Recombination
Meiotic recombination occurs at highly conserved recombination hotspots throughout the
genome [95]. A major determinant of these recombination sites is PR Domain Containing 9 (PRDM9)
binding, which primes the DNA for double strand break (DSB) and exchange of DNA between
chromosomes. This was shown in various mice studies as well as with human PRDM9 [29–31]. In mice,
Prdm9 mediates trimethylation of lysine 4 at histone 3 (H3K4me3) that, together with other factors,
mark chromatin for recombination [96]. This can subsequently recruit Spo11 to initiate a DSB to initiate
recombination in mice and yeast (Saccharomyces cerevisiae) [29,33,34]. The formation of a DSB is a
preceding event of the formation of the synaptonemal complex (discussed below). Interestingly, both
PRDM9 and SPO11 expression has been demonstrated in multiple cancer cell lines [32,35], and SPO11
is expressed in melanoma and cervical cancer tumors [36]. In addition, the human SPO11 gene is
found in chromosome 20q13.2–13.3, a region that is amplified in multiple breast cancers and associated
with genomic instability, such as aneuploidy, in breast cancer [97–100]. SPO11 is not entirely restricted
to male germ cells [101], thus it may also contribute functions unrelated to DSB formation.
Proteins involved in repairing the DSB generated during meiosis, such as Testis Expressed 15
(TEX15) and Disrupted Meiotic cDNA1 (DMC1), are also expressed in cancer. For instance, TEX15
and DMC1 expression are detected in melanoma, sarcoma and various carcinoma tumors [38,40].
In meiosis, Tex15 is responsible for the loading of DNA repair proteins (including Dmc1) onto the DNA
following DSB formation, shown in mice [37]. Due to this function, it works downstream of SPO11 and
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upstream of DMC1 (and other DNA repair proteins). Tex15 has shown limited expression outside the
testis (i.e., ovary, brain and uterus) in mice [38,102]. The recombinase DMC1 is a DNA repair protein
that associates with single stranded DNA after SPO11-mediated break and end-processing [39,103].
Through this association concurrent with RAD51 (another recombinase, though not meiosis-specific),
it searches for homolog sequences between homologous chromosomes and initiates strand invasion
wherein the cut DNA strand of a chromatid pair invades a homologous sequence of the other chromatid
pair. This, in turn, results in crossover or non-crossover of the flanking regions.
Meiosis Specific with OB Domains (MEIOB) was recently shown to be a DNA binding exonuclease
essential for meiotic recombination in synergy with SPATA22, and this protein has been detected in
different types of cancer cells [41–43]. This is in contrast to MEIOB and SPATA22 expression in normal
tissues and lung adenocarcinomas in which expression was found to be mutually exclusive [104].
Importantly, there was a positive correlation between MEIOB and the genome-wide burden of focal
copy number aberrations among samples from 10 cancer types with activation of MEIOB and SPATA22
expression. In vitro studies further demonstrated that MEIOB enhanced the oncogenic phenotype of
lung cancer cells. Moreover, the HORMA Domain Containing 1 (HORMAD1) protein has been linked
to genomic instability in cancer. Murine Hormad1 has multiple roles during meiotic recombination:
promoting homologue alignment/homologue search by ensuring DSB, facilitating formation of the
synaptonemal complex and recruitment of ATR checkpoint kinase activity to unsynapsed chromatin
in the meiotic recombination checkpoint [44,45]. In addition, the formation of the synaptonemal
complex mediates Hormad1 depletion, which is a requirement for progression beyond the first meiotic
prophase [45]. Its diverse expression in cancer includes multiple cancer cell lines from melanoma,
breast, lung, ovary and cervical carcinomas (data from the CT Gene Database) [48] and breast, lung,
esophageal, endometrial, bladder, colon and gastric carcinoma tumors [46–48]. As with MEIOB,
HORMAD1 has been associated with genomic instability in the form of allelic-imbalanced copy
number aberrations and was found to drive this type of genomic instability by modulating DNA
damage repair [47]. The homologous protein HORMA Domain Containing 2 (HORMAD2) also has
cancer-testis-associated expression profile [51]. In mice, Hormad2 has a localization pattern in the
nucleus similar to Hormad1, suggesting similar functions Hormad1 [49,50].
The proteins discussed above facilitate the exchange of genetic material between chromosomes
during meiosis through homologous recombination. A similar mechanism is present in somatic cells
to repair DNA damage, and the factors involved in both types of homologous recombination are
overlapping. The abnormal expression of one or several meiotic proteins in somatic cells could, in itself
or together with endogenously expressed factors, initiate inappropriate recombination events between
homologous chromosome structures (Figure 1). This could explain the chromosomal insertions,
deletions and translocations frequently observed in cancer cells, although further studies are needed
to confirm this.
2.2. Proteins Associated with the Synaptonemal Complex
The meiosis-specific synaptonemal complex is a tripartite protein structure that functions to
pair homologous chromosomes in the prophase of the first meiotic division. The synaptonemal
complex is a multipart structure built up by two lateral elements formed along the axes of the
homologous chromosomes and a central element, connected by transverse filaments (several reviews
of the synaptonemal complex structure have been published [105,106]). Briefly, the lateral elements
consist of Synaptonemal Complex Protein (SCP) 2 and SCP3, while the central elements consists
of Synaptonemal Complex Central Element Protein (SYCE) 1-3, Testis Expressed 12 (TEX12) and
transverse elements of SCP1. In addition, the lateral elements are associated with meiotic cohesins
as well as the above-mentioned HORMAD-proteins. Many of the proteins that constitute the
synaptonemal complex are aberrantly expressed in cancers. For example, SCP1 expression has
been described in brain, breast, renal cell, gastric, lung, stomach, and pancreatic carcinomas and
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melanoma (CT Gene Database) [57–63,107], and SCP3 is expressed in non-small cell lung cancers and
leukemia [53,54,108].
The cohesin protein complex is essential for tethering sister chromatids during mitosis, but it also
plays a role in meiosis, as depletion of the cohesin components Red8 and Rad21l in mice prevents
proper synaptonemal complex function [64,65]. The constitution of cohesin complexes involved in
mitosis and meiosis differs, and Structural Maintenance of Chromosomes 1β (Smc1β), Stromal Antigen
3 (Stag3), Rec8 and Rad21l are all subunits unique to meiosis-specific cohesin complexes in mice [66,67].
These proteins are also expressed in different types of cancer [32,35,68,109] and may interfere with the
normal function of cohesion during somatic cell mitosis.
Given the role of proteins of the synaptonemal complex and cohesin complexes in pairing of
chromosome pairs and sister chromatid tethering in meiosis, it is likely that they interfere with normal
chromosome alignment and segregation in mitosis and add to the aneuploidy often observed in cancer
(Figure 1). Proteins of the synaptonemal complex may also act in concert with proteins involved in
meiotic recombination to produce chromosome rearrangements.
2.3. Aurora Kinase C and the Chromosome Passenger Complex
Aurora Kinase C (AURKC) expression is largely limited to cells that undergo meiosis, as shown
in both human cells and mouse models [69,70], unlike its closely related family members, Aurora
Kinase A (AURKA) and Aurora Kinase B (AURKB), which are expressed in mitotic cells [110]. AURKC,
like the vast majority of genes described, is a cancer testis antigen [111]. Importantly, AURKC has
been shown to be oncogenic as it can transform NIH3T3 cells [110] and is expressed in multiple types
of cancer cells [71–74]. The contribution of AURKC to tumorigenesis remains elusive, but a direct
role in promoting genomic instability seems plausible. AURKC is a part of the meiotic chromosomal
passenger complex (CPC), important for centrosomal spindle assembly and bipolar orientation of
chromosomes during meiosis [112]. Similarly, the CPC of somatic cells, containing AURKB instead
of AURKC, is important for bipolar spindle assembly [113]. When AURKC is expressed in somatic
cancers, it can interfere with CPC function and spindle assembly checkpoint, likely through promoting
AURKB degradation [112]. In line with this, it was demonstrated that overexpression of AURKC in
mitotic cells leads to centrosome amplification and multinucleation [110]. As the CPC is important for
maintaining chromosome stability during cell division, loss of its function may result in aneuploidy,
chromosome imbalances and consequently cancer development [114] (Figure 1).
3. Testis Germ Cell Proteins Regulate Polyploidy and Maintain Mitotic Fidelity
In the absence of functional p53, DNA damaging treatments with cytotoxic or genotoxic
agents can induce polyploidy and a state of mitotic catastrophe, which is generally lethal to cancer
cells. However, some cells will survive long enough to undergo multipolar cell division and, in a
fraction of cells, depolyploidization results in continued viability [115,116]. One possible mechanism
contributing to this depolyploidization appears to be induced expression of meiotic genes. In a study
of radiation-induced mitotic catastrophe in various cancer cell lines, genes specifically associated
with meiosis were shown to be upregulated (i.e., SCP3, REC8 and DMC1) [40]. These results were
confirmed in a similar study based on lymphoma cells wherein additional meiotic genes were
found to be upregulated in association with mitotic catastrophe (i.e., MOS, STAG3 and SCP1) [117].
The role of REC8 in escape from mitotic catastrophe has been further examined. Mouse Rec8 is
important for the segregation of sister chromatids during meiosis and thereby promotes reductional
cell division in meiosis [118]. In polyploidy cancer cells, resulting from irradiation-induced mitotic
catastrophe, REC8 was associated with centrosomes and spindle poles, further advocating for a role in
depolyploidization [119]. Thus, current results suggest that activation of a meiotic program may help
tumor cells balance polyploidy.
Interesting, testis germ cell proteins may play yet another role in managing the gross chromosomal
abnormalities of cancers cells. Acrosin Binding Protein (ACRBP) was shown to support mitotic fidelity
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and promote resistance towards paclitaxel in ovarian cancer [120,121]. Further studies demonstrated
that ACRBP antagonizes Nuclear Mitotic Apparatus Protein 1 (NUMA1) function in abrogating the
mitotic spindle assembly and thereby reinforces bipolar spindle assembly in the presence of paclitaxel.
ACRBP exhibits a broad expression pattern in several cancers, including ovarian, lung (NSCLC), breast,
bladder, colon and liver, and high expression of ACRBP is associated with a poor clinical outcome in
ovarian cancer patients with reduced survival time and faster relapse [81,121]. Additionally, the testis
germ cell proteins Fragile X Mental Retardation 1 Neighbor (FMR1NB), Nuclear RNA Export Factor
2 (NXF2), Melanoma Antigen Family A5 (MAGEA5), Fibrous Sheath Interacting Protein 1 (FSIP1),
Transforming, Acidic Coiled-Coil Containing Protein 3 (TACC3) and START Domain Containing 6
(STARD6) have a role in mitotic fidelity in cancer cells [82]. Depletion of these proteins from cancer cell
lines resulted in the generation of multipolar spindles and induction of micronucleation in response to
low doses of paclitaxel. Furthermore, depletion of TACC3 in cells with p53 deletion and/or RASV12
expression increased mitotic transit time and enhanced the frequency of abnormal mitosis. These
results clearly demonstrate that cancer cells evolve to depend on testis germ cell proteins for accurate
chromosome segregation in the presence mitotic stress (Figure 1).
4. Oncogenic Testis Proteins May Promote Replication Stress
Although not directly implicated in genome maintenance, oncogenes may promote genomic
instability. There is mounting evidence that oncogenes can induce replication stress in premalignant
lesions and cancers, which, in turn, can result in DNA damage and genomic instability [122].
At certain stages of their lifecycle, germ cells are highly proliferative. This is especially true for
spermatogonia (i.e., undifferentiated adult male germ cells), which proliferate throughout adult
life. It can be speculated that these cells maintain a high level of mitogenic signaling and may
express proteins with oncogenic potential. Interestingly, many genes specifically expressed in the
spermatogonia are also ectopically activated in multiple types of cancer and, indeed, some of these
exhibit oncogenic features [20,123]. For instance, CAGE, MAGE-C, NY-SAR-35, etc. promote cancer cell
proliferation [110,124–126]. Recent results from our group and others suggest that germ cell proteins
with oncogenic potential can induce genomic instability in cancer cells in a similar manner to classic
oncogenes like those encoding Ras, Myc and Cyclin E [122]. We have demonstrated that knockdown of
the SSX2 gene significantly reduced the proliferation of melanoma cells [125], consistent with another
study showing that SSX proteins activate several important mitogenic signaling pathways, such as
MAPK and Wnt [127]. We further found that ectopic expression of SSX2 in different cell lines induced
DNA damage and, in turn, promoted either a senescence response or genomic instability [125]. In A375
melanoma cells, the underlying course of this phenotype seemed to be replication stress translating
into mitotic defects. Whether SSX proteins, or other testis proteins with oncogenic potential, have any
role in genomic instability in tumors and contribute to cancer progression remains to be determined.
5. Conclusions and Future Perspectives
For cancer cells to exploit genome instability to support tumorigenesis, they must maintain
viability and productive mitosis in the presence of gross chromosomal abnormalities. Thus, exploring
how cancer cells regulate genomic instability is highly relevant to our understanding of cancer
development. Furthermore, many of the currently used treatments induce massive DNA damage and
genomic instability to drive cancer cells into apoptosis, and knowledge of how cancer cells cope with
these challenges may help us understand drug resistance mechanisms and improve current strategies
for cancer treatment. As discussed in this review, current evidence strongly suggests that the activation
of testis germ cell genes plays an important role in several aspects of how cancer cells handle genomic
instability. During meiosis, germ cell proteins work in concert to carry out DNA breaks, crossover of
genetic material and pairing and segregation of chromosomes/chromatids. Testis germ cell proteins
are often co-expressed in cancers and it seems plausible that they also functionally interact in cancers
to produce genomic instability. Many of these testis germ cell proteins are strictly limited to germ cells
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in their expression and therefore represent nearly cancer-specific targets. Thus, they are particularly
promising as targets for cancer immunotherapy since their germ cell expression does not seem to
induce immunological tolerance and allows generation of immune responses in cancer patients [20].
Furthermore, numerous cancer vaccination trials targeting testis germ cell proteins have not shown
any effects on spermatogenesis or in any somatic tissue, thus testis germ cell proteins remain ideal
candidates for specific targeting of cancer cells. Our current understanding of tumor immunology
suggests that immunologic pressure on tumors may result in the evolution of antigen-negative escape
variants, highlighting the potential benefits of targeting antigens that, if lost, would reduce the ability of
the cancer to further progress [22]. Thus, targeted therapy aimed at proteins supporting basic hallmarks
of cancer will likely be highly efficient, and may include testis germ cell proteins regulating genomic
instability during cancer development. Such treatment may be combined with DNA damage-inducing
agents for synergistic effects. Testis germ cell proteins may therefore be used for development of novel
types of highly-specific and effective targeted therapy.
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